

Diphtheria - Pipeline Review, H2 2020

<https://marketpublishers.com/r/D520F9DECEFEN.html>

Date: November 2020

Pages: 85

Price: US\$ 2,000.00 (Single User License)

ID: D520F9DECEFEN

Abstracts

Diphtheria - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H2 2020, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 4, 9, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Diphtheria - Overview
- Diphtheria - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diphtheria - Therapeutics Assessment
- Assessment by Target
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diphtheria - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Biken Co Ltd
- Biological E Ltd
- BioNet-Asia Co Ltd
- Boryung Pharmaceutical Co Ltd
- Cadila Healthcare Ltd
- CanSino Biologics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chongqing Zhifei Biological Products Co Ltd
- Emergent BioSolutions Inc
- GC Pharma
- GlaxoSmithKline Plc
- KM Biologics Co Ltd
- LG Chem Ltd
- Novo Medi Sciences Pvt Ltd
- Olymvax Biopharmaceuticals Inc
- Panacea Biotec Ltd
- Sanofi
- Serum Institute of India Ltd
- Shantha Biotechnics Pvt Ltd
- VaxForm LLC
- Yisheng Biopharma Co Ltd

Diphtheria - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B])

vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adacel plus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diphtheria antitoxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTcP vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3104A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3111A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-315 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diphtheria - Dormant Projects

Diphtheria - Discontinued Products

Diphtheria - Product Development Milestones

Featured News & Press Releases

Mar 11, 2019: LG Chem gets \$33.4 mil. from Gates Foundation for vaccine development

Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Diphtheria, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Diphtheria - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2020
Diphtheria - Pipeline by Biken Co Ltd, H2 2020
Diphtheria - Pipeline by Biological E Ltd, H2 2020
Diphtheria - Pipeline by BioNet-Asia Co Ltd, H2 2020
Diphtheria - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
Diphtheria - Pipeline by Cadila Healthcare Ltd, H2 2020
Diphtheria - Pipeline by CanSino Biologics Inc, H2 2020
Diphtheria - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020
Diphtheria - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
Diphtheria - Pipeline by Emergent BioSolutions Inc, H2 2020
Diphtheria - Pipeline by GC Pharma, H2 2020
Diphtheria - Pipeline by GlaxoSmithKline Plc, H2 2020
Diphtheria - Pipeline by KM Biologics Co Ltd, H2 2020
Diphtheria - Pipeline by LG Chem Ltd, H2 2020
Diphtheria - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2020
Diphtheria - Pipeline by Olymvax Biopharmaceuticals Inc, H2 2020
Diphtheria - Pipeline by Panacea Biotec Ltd, H2 2020
Diphtheria - Pipeline by Sanofi, H2 2020
Diphtheria - Pipeline by Serum Institute of India Ltd, H2 2020
Diphtheria - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2020
Diphtheria - Pipeline by VaxForm LLC, H2 2020
Diphtheria - Pipeline by Yisheng Biopharma Co Ltd, H2 2020
Diphtheria - Dormant Projects, H2 2020
Diphtheria - Dormant Projects, H2 2020 (Contd..1), H2 2020

Diphtheria - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diphtheria, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

I would like to order

Product name: Diphtheria - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/D520F9DECEFEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D520F9DECEFEN.html>